Aclaris Therapeutics, Inc. (ACRS) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$3.28

From 52W high−46.79%

Volume1.74M

Market cap$512.25M

P/E (TTM)—

P/S (TTM)62.3x

Div yield—

Key dataOct 19, 2026

Open

$3.28

From 52W high

−46.79%

Volume

1.74M

Market cap

$512.25M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.6x

P/E (TTM)

—

RSI (14)

30.6

MomentumView details →

1D Return

+6.10%

YTD Return

+12.29%

SummaryUpdated Jun 1, 2026

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Wayne, Pennsylvania. The company went public in October 2015 and focuses on developing novel drug candidates for immune-inflammatory diseases. Aclaris operates through two business segments: a Therapeutics division that develops innovative therapies for significant unmet medical needs in immuno-inflammatory conditions, and a Contract Research segment that provides laboratory services to generate additional revenue while advancing its core drug development mission.

Ask drillr about Aclaris Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.6x

EV/Sales

51.2x

P/S (TTM)

62.3x

P/B (TTM)

4.1x

ProfitabilityView details →

Gross Margin

95.61%

Net Margin

−921.50%

EBITDA Margin

−916.38%

ROE (TTM)

−60.79%

ROA (TTM)

−42.15%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

−51.05%

EPS YoY

+57.66%

FCF YoY

−33.16%

Revenue CAGR 3Y

−35.93%

EPS CAGR 3Y

+69.01%

EBITDA YoY

−30.15%

MomentumView details →

1D Return

+6.10%

YTD Return

+12.29%

1Y Return

+68.16%

RSI (14)

30.6

vs 50D SMA

−35.88%

vs 200D SMA

−24.56%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

3.46x

Quick Ratio

3.46x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.15

EPS Surprise

6.25%

Beats (12Q)

7/12

Next Q EPS Est

−$0.17

Avg Surprise (4Q)

3.15%

Rev Surprise

17.80%

Financials snapshotView financials →

Revenue (TTM)

8.22M

Net Income (TTM)

−75.74M

Op. CF (TTM)

−62.06M

Next earningsNov 5, 2026 →

Latest newsMore news →

Aclaris Therapeutics (ACRS) shares surged 6.0% in the latest trading session on above-average volume.34d ago

Aclaris Therapeutics reported its Q2 2026 financial results, with total revenue of $1.6 million and a net loss of $21.5 million.75d ago

Similar companies

China Biotech Services Holdings Limited08037.HK Fulgent Genetics, Inc.FLGT Myriad Genetics, Inc.MYGN Yunkang Group Limited02325.HK Prenetics Global LimitedPRE Castle Biosciences, Inc.CSTL Find similar companies →

Latest newsMore news →

Aclaris Therapeutics (ACRS) shares surged 6.0% in the latest trading session on above-average volume.34d ago Aclaris Therapeutics reported its Q2 2026 financial results, with total revenue of $1.6 million and a net loss of $21.5 million.75d ago